Key facts
- Versa Vascular’s last known valuation is $96.0M (May 2025).
- It has raised $49.9M; the latest was Later Stage VC ($27.3M) in May 2025.
- Notable investors include S3 Ventures, BioStar Capital, Cadence Healthcare Ventures, Occam Labs (Santa Cruz), Santa Cruz Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Versa Vascular
- ·The full record, as it builds
Funding rounds
No funding rounds for Versa Vascular are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Versa Vascular
Developer of an implant system designed to treat tricuspid regurgitation by supporting native valve function without disrupting cardiac structures. The company's system offers a steerable catheter for implant placement, device controls for simplified procedures, and an atrial-only implant design, enabling cardiologists to treat a wider range of patients with reduced procedural risk and improved outcomes.
- Sector
- Healthcare
- HQ
- Santa Cruz, CA, United States
- Founded
- 2020
- Employees
- 17
- Website
- versavascular.com/
- Ownership
- Privately Held (backing)
Versa Vascular doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Versa Vascular shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Versa Vascular in its N-PORT filings yet. We sweep new filings monthly.